Clinical trial with traditional Chinese medicine intervention ''tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'' for chronic hepatitis B-associated liver failure

Table 2 Antiviral therapy in groups n (%)

Nucleoside drugs	MMC group (n = 31)	“TQD” group (n = 65)	“TTK” group (n = 36)
Not using nucleoside drugs	21 (67.74)	55 (84.62)	27 (75.00)
Using nucleoside drugs	10 (32.26)	10 (15.38)	9 (25.00)
Lamivudine	12 (38.71)	30 (46.15)	12 (33.33)
Adefovir	0 (0.00)	5 (7.69)	4 (11.11)
Telbivudine	2 (6.45)	6 (9.23)	1 (2.78)
Entecavi	6 (19.35)	12 (18.46)	5 (13.89)
Lamivudine combined with adefovir	1 (3.23)	1 (1.54)	5 (13.89)
Entecavir combined with adefovir	0 (0.00)	1 (1.54)	0 (0.00)

There was no difference among the three groups in using nucleoside drugs in the study (P = 0.153).